of chromosomal material, on the other hand, is often ascribed hematologic malignancies.
Materials and methods Introduction
Cytogenetic studies
Cytogenetic investigations of hematologic malignancies have
Bone marrow and/or peripheral blood cells were adjusted to been instrumental in delineating genomic sites harboring a concentration of 10 6 /ml and cultured for 24 and 48 h in genes that, if structurally rearranged or otherwise deregulated, McCoy's 5A medium supplemented with 20% fetal calf are intimately associated with the neoplastic process. 1 Analyserum, L-glutamine, and antibiotics. In one patient (case 10, ses aiming at identifying these genes have been particularly at relapse) leukemic cells from a pleural effusion were anafruitful in the elucidation of the karyotypically balanced lyzed. Cells from minced lymph nodes were cultured in the abnormalities, ie translocations, insertions, and inversions, same medium, but only for 24 h and in a concentration of and during the last few years a large number of hybrid genes 2 × 10 6 /ml. Chromosome preparations were made in a stangenerated through such recombinations has been reported. 2, 3 dard manner and banded by trypsin-Giemsa. In the subMolecular studies of cytogenetically unbalanced aberrations, sequent chromosome analysis, the clonality criteria and the such as duplications, trisomies, deletions, and monosomies, description of karyotypes followed the recommendations of have proved less successful. In fact, next to nothing is known ISCN (1995) . 20 about the pathogenetically important molecular consequences of abnormalities resulting in gain of chromosomal material even though such changes are frequent in hemato-translocations, and additional material of unknown origin had been treated with RT due to breast cancer 4 years prior to the AML diagnosis; cases 7, 9, and 10 displayed 3p loss at replacing a 3p segment, were retrieved and reviewed. Malignancies with aberrations only resulting in loss of the entire relapse, after AML treatment and bone marrow transplantation with cyclophosphamide and total body irradiation, or busulshort arm of chromosome 3, ie isochromosome formation of 3q and monosomy 3, were excluded because such changes fan, as conditioning regimens; case 11 had received treatment with RT 8 years previously due to testicular seminoma; and are uninformative with regard to specific 3p regions deleted. Clinical information, including sex, age, morphology, 21-23 B case 13 displayed the 3p deletion in blastic crisis of CML, after busulfan and interferon-␣ therapy. Seven B cell lymphoid or T cell lineage involvement, and prior genotoxic treatment, ie chemo (CT)-and/or radiotherapy (RT) among the patients malignancies (three ALL, one CLD, and three NHL) were identified ( in two cases with inv(16)(p13q22). Fifty-seven of the 76 cases had well defined breakpoints, and the losses incurred, together with our 10 cases, are depicted in Figure 1 . The freDeletion map quencies of deleted bands are given in Table 3 . 3p loss was detected in 30 (1.3%) of the 2285 MDS in the A deletion map of 3p was made for the following disorders: AML, MDS, CMD, Philadelphia chromosome-positive chronic data bank: six MDS-NOS (1.4%), three refractory anemia (RA; 0.5%), two refractory anemia with ringed sideroblasts (RARS; myeloid leukemia (CML), ALL, CLD, Hodgkin's disease (HD), and NHL. Only malignancies with well characterized abnor-1.2%), nine refractory anemia with excess of blasts (RAEB; 1.4%), two chronic myelomonocytic leukemia (0.8%), and malities were included, ie aberrations with uncertain breakpoints were excluded. This notwithstanding, it should be eight refractory anemia with excess of blasts in transformation (RAEBt; 3.1%) (P Ͼ 0.05). Seven of the 30 cases (23%) were stressed that published breakpoints, although assigned to specific chromosome bands, may well differ due to quality differtreatment-related (two CT only, four CT + RT, and one not specified), a frequency higher but not statistically different ences among cytogenetic laboratories and banding techniques used. When a case had more than one abnormality leading (P Ͼ 0.05) from the total incidence (13%; 305/2285) of tMDS in the data base. The 3p abnormality was found as the sole to 3p loss, the largest deletion was depicted.
karyotypic change in two MDS and together with other aberrations in the remaining 28, most often (Ͼ10%) −5 (15 cases), +8 (seven cases), −12 and −17 (six cases), del(5q) (five cases), Results −7 and −9 (four cases), and −18 (three cases). Sixteen of the 30 cases had well defined breakpoints, and their deletions, A total of 20 hematologic malignancies with 3p loss were identified. Thirteen were myeloid disorders (Table 1) : 10 AML, together with our two cases, are shown in Figure 1 . The frequencies of deleted bands are given in Table 3 . two MDS, and one CML, constituting 2.9% (10/349) of AML with clonal chromosomal abnormalities, 0.7% (2/295) of Partial loss of 3p was found in seven (0.8%) of the 840 CMD published cases in the data bank: three CMD-NOS (0.9%), MDS, and 1.0% (1/96) of CML with aberrations in addition to the t(9;22) analyzed at our Department. The 3p abnormality three polycythemia vera (1.0%), and one idiopathic myelofibrosis (0.6%). The 3p abnormality was the sole karyotypic occurred together with other changes in all 13 cases, apparently secondary to the well known primary changes change in four cases and occurred together with other aberrations in three CMD; no other recurrent additional changes inv(3)(q21q26), t(6;9)(p23;q34), t(8;16)(p11;p13), t(9;22) (q34;q11), and t(15;17)(q22;q12-21) in five of them (cases 5-were seen among the latter. Six of the seven CMD had well defined breakpoints ( Figure 1 ). The frequencies of deleted 7, 9, and 13; Table 1 ). Seven of the patients had been treated with CT and/or RT before the occurrence of the 3p rearrangebands are given in Table 3 . 3p loss was detected in 13 (0.7%) of the 1894 CML with ment: case 2 had received treatment with prednimustine and methotrexate 20 months previously because of NHL; case 3 abnormalities in addition to the t(9;22) in the data bank. In six cases, the 3p loss was the only additional aberration; none with t(1;14)(p34;q11), t(8;14)(q24;q32), and t(11;14)(q13;q32) and in two cases with t(14;18)(q32;q21). Lineage involvement of the other secondary anomalies were recurrent among the remaining CML. Seven of the 13 CML had well defined breakwas reported in 16 of the 23 cases; 13 were B cell (0.9% of the 1381 cytogenetically abnormal B lineage ALL in the data points, and their deletions, together with our case, are depicted in Figure 1 . The frequencies of deleted bands are bank) and three were T cell (0.7% of the 401 T lineage ALL) (P Ͼ 0.05). Sixteen of the 23 cases had well defined breakgiven in Table 3 .
Aberrations leading to partial 3p loss were found in 23 points, and the losses incurred, together with our three cases, are shown in Figure 1 . The frequencies of deleted bands are (0.6%) of the 3589 ALL included in the data bank; nine ALL-NOS (0.5%), nine ALL-L1 (0.9%), three ALL-L2 (0.5%), and given in Table 3 . 3p losses were detected in 39 (2.4%) of the 1602 CLD in two ALL-L3 (1.0%) (P Ͼ 0.05). The 3p abnormality was found as the sole anomaly in three cases. Among the remaining 20 the data bank: one CLD-NOS (4.0%), 14 chronic lymphocytic leukemias (2.0%), six adult T cell leukemias (3.2%), three pro-ALL the most frequent additional aberrations (Ͼ10%) were: del(6q), −12, −16, −17, and −19 (four cases), and −4, −5, −7, lymphocytic leukemias (3.2%), two hairy cell leukemias (2.8%), seven mycosis fungoides/Sé zary syndrome (7.1%), −8, and +21 (three cases). The 3p loss occurred in single ALL
Figure 1
Deletion map of 3p in hematologic malignancies. For abbreviations, see text. 88  92  3p24  69  83  50  63  79  73  88  70  3p23  73  78  50  75  68  73  75  63  3p22  67  78  50  63  63  65  75  63  3p21  69  72  50  75  58  65  63  59  3p14  48  44  67  63  32  42  50  31  3p13  40  44  50  50  21  38  50  27  3p12  24  33  33  13  11  23  25  14  3p11  13  22  17  0  5  8  0  8 AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CMD, chronic myeloproliferative disorder; CML, Philadelphia chromosomepositive chronic myeloid leukemia; ALL, acute lymphoblastic leukemia; CLD, chronic lymphoproliferative disorder; HD, Hodgkin disease; NHL, non-Hodgkin lymphoma. The frequencies of the chromosome bands most often deleted in each malignancy are denoted in bold type.
one Waldenström macroglobulinemia (2.2%), and five Aberrations leading to partial 3p loss were found in eight (4.5%) of the 178 HD in the data bank: one HD-NOS (3.4%), multiple myelomas (1.5%) (P Ͼ 0.05). The 3p loss was found as the sole anomaly in five cases. Among the remaining 34 three mixed cellularity (6.4%), and four nodular sclerosis (4.9%). The 3p abnormality was the sole karyotypic change in CLD the most frequent (Ͼ10%) additional aberrations were: del(6q) (eight cases), −8 and −10 (seven cases), −X and −22 one case. Among the remaining seven HD, the most common additional aberrations were −13 (four cases), and i(1q), −8, (six cases), del(1q), del(13q), inv(14)(q11q32), −17, and −21 (five cases), and −9, t(11;14)(q13;q32), and +12 (four cases).
−10, and −16 (three cases). All eight HD had well defined breakpoints ( Figure 1 ). The frequencies of deleted bands are Lineage involvement was reported in 37 of the 39 CLD; 25 were B cell (2.7% of the 912 cytogenetically abnormal B lingiven in Table 3 . 3p losses were detected in 74 (3.1%) of the 2394 NHL eage CLD in the data bank) and 12 were T cell (4.2% of the 288 T lineage CLD) (P Ͼ 0.05). Twenty-five of the 39 cases included in the data bank: six NHL-NOS (1.9%), 20 low-grade NHL (3.0%), 29 intermediate-grade NHL (3.9%), and 19 highhad well defined breakpoints, and their deletions, together with our case, are depicted in Figure 1 . The frequencies of grade NHL (2.8%) (P Ͼ 0.05). The 3p loss was found as the sole anomaly in one case. Among the remaining 73 NHL, the deleted bands are given in Table 3 . most frequent additional aberrations (Ͼ10%) were: del(6q) (19 cytogenetically abnormal hematologic malignancies included in the Cancer Chromosome Data Bank; 4 neoplasms with specases), t(14;18)(q32;q21) (13 cases), −4 (12 cases), −15 and −17 (11 cases), −Y, +X, and +12 (10 cases), del(1p), −6, and cific chromosomal abnormalities may more often be published. In some instances, as exemplified by our cases 7, 9-−13 (nine cases), and −18 and +18 (eight cases). The 3p deletions also occurred together with the characteristic 11, 13, 16, and 17 (Tables 1 and 2 ), the 3p abnormalities were seen only in subclones and/or during relapse/progression. This t(3;22)(q27;q11) (one case), t(8;14)(q24;q32) (four cases), t(8;22)(q24;q11) (one case), and t(11;14)(q13;q32) (four strongly indicates that 3p deletions are secondary aberrations in hematologic malignancies, ie they arise during clonal evocases). Lineage involvement was reported in 59 of the 74 NHL; 48 were B cell (3.7% of the 1291 cytogenetically abnorlution and tumor progression. As alluded to above, however, the phenotypic impact of these changes remains to be clarimal B lineage NHL in the data bank) and 11 were T cell (3.2% of the 340 T lineage NHL) (P Ͼ 0.05). Sixty-four of the 74 fied. We have previously suggested that primary chromosomal abnormalities in most hematologic disorders are balanced, cases had well defined breakpoints, and the deletions incurred, together with our three cases, are shown in Figure  whereas secondary aberrations are unbalanced. 33 The present finding of an evolutionary role of 3p loss fits well with this 1. The frequencies of deleted bands are given in Table 3. suggestion. If this is correct, then submicroscopic 'primary' changes should be actively sought in hematologic malignancies with 3p deletions as the sole anomaly. In fact, in one Discussion previously reported case -an AML-M3 with an unbalanced 3;8 translocation as the single aberration -a cytogenetically The present compilation of hematologic malignancies with cytogenetic abnormalities resulting in deletion of 3p material undetectable PML/RARA fusion was detected by molecular means.
34
revealed that (1) such losses occur in 0.6-4.5% of the cases, ie, with frequency differences among, and to some extent 3p losses were more frequent in tAML than in de novo AML, and a similar trend was noted in MDS, although the incidence within, the different disease groups; (2) the vast majority of 3p deletions are found together with other abnormalities; (3) 3p differences between tMDS and de novo MDS did not reach statistical significance. This association between 3p deletions losses in AML are strongly associated with previous genotoxic therapy; and (4) that the deletion hot spots are the distal chroand prior genotoxic treatment in the form of CT and/or RT agrees well with the notion that 3p abnormalities, losses as mosome bands 3p25 and 3p26 in all but one of the disorders.
The incidence of rearrangements leading to loss of 3p difwell as balanced rearrangements, may be particularly frequent in secondary AML and MDS, as has been suggested in some fered significantly (P Ͻ 0.001) among the various malignancies -from 0.6% in ALL to 4.5% in HD, with higher previous studies. [35] [36] [37] [38] [39] [40] The finding that the 3p deletions in both AML and MDS frequently occurred together with del(5q) and frequencies in the chronic lymphoproliferative disorders and the lymphomas than in the chronic myeloid disorders and the monosomies for chromosomes 5 and 7 -well known therapyassociated abnormalities in these disorders 26 -provides acute leukemias. In general, the incidences of 3p deletions did not differ among the morphologic subgroups of the hemafurther evidence in favor of 3p loss as a treatment-related abnormality. Furthermore, a particular association with tologic disorders. The only exception was AML, in which the frequencies varied significantly among the FAB groups, from alkylating agents is also suggestive since losses of part or all of chromosomes 5 and 7 in tAML and tMDS occur mainly 0.3% in AML-M3 and AML-M4 to 5.3% in AML-M6. Thus 3p loss does not, except in AML, seem to affect the morphology after such therapy. 41 In fact, among the cases compiled where type of prior CT was reported, an alkylating agent, such as or the stage of maturation arrest of myeloid and lymphoid neoplasms. The finding that 3p deletions occur equally often cyclophosphamide, lomustine, melphalan, and procarbazine, was often included in the regimen. It is also noteworthy that in B and T cell ALL, CLD, and NHL also strongly indicates that such abnormalities confer a similar selective advantage 3p deletions were found in a substantial proportion of tAML/tMDS occurring after treatment with RT only. We thus for neoplastic cells arising from these lineages, ie irrespective of origin. Furthermore, the present results suggest that 3p conclude that 3p losses in tAML and tMDS are particularly associated with previous RT and/or CT including alkylating losses do not, at least not to any larger extent, correlate with disease progression, since no significant frequency differences agents. 3p25-26 were the most frequently deleted chromosome were detected among the MDS subtypes, between MDS and AML, or among the low-, intermediate-, and high-grade NHL.
bands in all disease groups except CMD, in which a more proximal deletion hot spot (3p14) was found ( Figure 1 ; Table  The latter finding is, to some degree, in contrast to a previous study of NHL, in which aberrations of chromosome 3, includ-3). Loss of functional tumor suppressor proteins, encoded by genes on 3p25-26, may hence be involved in the pathogenesis ing deletions affecting the short arm, were associated with leukemic phase and thus clinical progression. 32 That investiof hematologic malignancies with cytogenetic abnormalities resulting in 3p loss. As yet, no candidate TSG in this region gation, however, included only 16 cases of which only a minority displayed 3p loss; most of the chromosome 3 abnorhas been identified, or even suggested, in myeloid or lymphoid disorders. It is of interest, however, that the VHL gene is malities actually involved 3q. It is important to stress in this context that the prognostic importance of 3p deletions could located within this region, 16 but, to the best of our knowledge, no VHL mutations have been described in hematologic maligunfortunately not be analyzed, due partly to the lack of information regarding survival in most of the published cases and nancies. In epithelial tumors, on the other hand, several putative TSG on 3p have been implicated. 18 However, the 3p partly to the heterogeneous treatment regimens used.
The vast majority of the 3p losses occurred together with deletion hot spots in solid neoplasms seem to be more proximal than those in hematologic malignancies. A recent compiother chromosomal aberrations, occasionally with well known disease-associated, primary changes, such as t(8;21), lation of chromosomal imbalances in solid tumors revealed that the most frequently deleted region was 3p12-21, although t(9;11), and inv (16) in AML, t(1;14) and t (8;14) in ALL, t (11;14) and inv (14) in CLD, and t(8;14), t(11;14), and t(14;18) in NHL.
an additional deletion peak could be detected at 3p25-26 in breast cancer, malignant melanoma, and brain tumors.
42
To some degree this may be due to a biased reporting of the 
